Navigation Links
Bioenergy D-Ribose Achieves Highest Safety Standard
Date:11/20/2008

MINNEAPOLIS, Nov. 20 /PRNewswire/ -- Integrative life science company Bioenergy, Inc. has achieved GRAS status (generally recognized as safe) from the U.S. Food and Drug Administration (FDA) for its core energy nutrient D-ribose, a naturally occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP) -- an essential energy compound.

"The FDA's written response that it has reviewed the submitted safety evidence and has no questions about the GRAS determination for D-ribose is the government's highest recognition of a food ingredient for safety and purity," said Raj Khankari, Ph.D., CEO of Bioenergy, Inc. The company has held "self-affirmed" GRAS status for years. "Today, we are gratified that the FDA has officially validated our assessment."

"The FDA's 'no questions letter' signals to the major food and beverage manufacturers that we have invested all the resources possible to guarantee the quality and safety of our D-ribose products for the benefit of customers and consumers."

Bioenergy has amassed a large body of scientific literature regarding uses of ribose for people across all age and health categories. The company has more than 40,000 customers for its proprietary Corvalen products alone, and millions worldwide use Bioenergy ribose in other products. It is commonly found in functional foods like energy bars (Detour, FastFuel, Marathon) and beverages (SoBe Adrenaline Rush, Vitamin Water, Snapple Antioxidant Water). Currently, Bioenergy D-ribose is included as an ingredient in approximately 100 products.

In larger quantities as a Medical Food, D-Ribose also has been shown to assist patients with compromised heart function and is also widely used by patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS).

Bioenergy, Inc. (http://www.bioenergy.com) is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose for health and wellness. In addition to a pharmaceutical subsidiary, Bioenergy has two other companies. Bioenergy Life Science, Inc. manufactures and sells D-ribose as an ingredient to nutraceutical firms for beverages and foods; as a medical food through doctors and clinics; and as a dietary supplement for energy recovery (reduces fatigue, muscle pain, soreness and stiffness following exercise). Viacell, LLC is developing technology related to the enhancement of blood components.


'/>"/>
SOURCE Bioenergy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Media Advisory - Atlantica BioEnergy Task Force Leaders Roundtable
2. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
3. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
4. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
5. Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock
6. Raj Khankari Named Bioenergy, Inc., CEO
7. Atlantica BioEnergy Task Force Unveiled
8. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
9. BioEnergy International Facility Opens in Bay State
10. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
11. D-Ribose Helps Energy-Starved Hearts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):